GlassScriptPhysician profile
Matthew P Borst
NPI 1770575474
$2,478.81
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,809 · 2020: $670.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tesaro, INC. | $750.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $499.35 | 2019-2020 | |
| Clovis Oncology, INC. | $397.29 | 2019-2020 | |
| Abbvie INC. | $216.38 | 2019 | |
| Myriad Genetic Laboratories, INC. | $119.42 | 2020 | |
| Merck Sharp & Dohme LLC | $110.96 | 2019 | |
| Heron Therapeutics, INC. | $99.57 | 2019 | |
| Intuitive Surgical, INC. | $64.48 | 2019 | |
| Eisai INC. | $49.76 | 2019 | |
| Rigel Pharmaceuticals, INC. | $27.69 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.22 | 2019 | |
| Amgen INC. | $19.97 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $17.83 | 2019 | |
| Celgene Corporation | $17.78 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $16.25 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $14.74 | 2019 | |
| Lilly USA, LLC | $13.19 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.13 | 2019 | |
| Jazz Pharmaceuticals INC. | $11.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Borst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.